Retrophin (RTRX) to Acquire Orphan Technologies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- Houthi strike on Saudi airport kills 12, worst attack on kingdom in a decade
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake shakes nation, but avoids major destruction
- Nio stock jumps after Goldman Sachs upgrade to buy
Retrophin Announces Agreement to Acquire Orphan Technologies
October 22, 2020 4:02 PM EDTAgreement adds OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria
Compelling strategic fit that will expand pipeline of potential first-in-class therapies targeting rare diseases
Retrophin to host conference call and webcast today at 5:00 p.m. ET
SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has... More



